BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 29584670)

  • 1. Computational Simulation Studies on the Binding Selectivity of 1-(1H-Benzimidazol-5-yl)-5-aminopyrazoles in Complexes with FGFR1 and FGFR4.
    Pan YL; Liu YL; Chen JZ
    Molecules; 2018 Mar; 23(4):. PubMed ID: 29584670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Theoretical studies on FGFR isoform selectivity of FGFR1/FGFR4 inhibitors by molecular dynamics simulations and free energy calculations.
    Fu W; Chen L; Wang Z; Kang Y; Wu C; Xia Q; Liu Z; Zhou J; Liang G; Cai Y
    Phys Chem Chem Phys; 2017 Feb; 19(5):3649-3659. PubMed ID: 28094372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural insights into FGFR kinase isoform selectivity: diverse binding modes of AZD4547 and ponatinib in complex with FGFR1 and FGFR4.
    Tucker JA; Klein T; Breed J; Breeze AL; Overman R; Phillips C; Norman RA
    Structure; 2014 Dec; 22(12):1764-1774. PubMed ID: 25465127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insight into resistance mechanisms of AZD4547 and E3810 to FGFR1 gatekeeper mutation via theoretical study.
    Liang D; Chen Q; Guo Y; Zhang T; Guo W
    Drug Des Devel Ther; 2017; 11():451-461. PubMed ID: 28255231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy.
    Quintanal-Villalonga Á; Ferrer I; Guruceaga E; Cirauqui C; Marrugal Á; Ojeda L; García S; Zugazagoitia J; Muñoz-Galván S; Lopez-Rios F; Montuenga L; Vicent S; Molina-Pinelo S; Carnero A; Paz-Ares L
    EBioMedicine; 2020 Mar; 53():102683. PubMed ID: 32114392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors.
    Tan L; Wang J; Tanizaki J; Huang Z; Aref AR; Rusan M; Zhu SJ; Zhang Y; Ercan D; Liao RG; Capelletti M; Zhou W; Hur W; Kim N; Sim T; Gaudet S; Barbie DA; Yeh JR; Yun CH; Hammerman PS; Mohammadi M; Jänne PA; Gray NS
    Proc Natl Acad Sci U S A; 2014 Nov; 111(45):E4869-77. PubMed ID: 25349422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developing FGFR4 inhibitors as potential anti-cancer agents via in silico design, supported by in vitro and cell-based testing.
    Ho HK; Németh G; Ng YR; Pang E; Szántai-Kis C; Zsákai L; Breza N; Greff Z; Horváth Z; Pató J; Szabadkai I; Szokol B; Baska F; Őrfî L; Ullrich A; Kéri G; Chua BT
    Curr Med Chem; 2013; 20(10):1203-17. PubMed ID: 23409720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular simulation studies on the binding selectivity of 2-anilino-4-(thiazol-5-yl)-pyrimidines in complexes with CDK2 and CDK7.
    Chohan TA; Qian HY; Pan YL; Chen JZ
    Mol Biosyst; 2016 Jan; 12(1):145-61. PubMed ID: 26565382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crystal Structure of the FGFR4/LY2874455 Complex Reveals Insights into the Pan-FGFR Selectivity of LY2874455.
    Wu D; Guo M; Philips MA; Qu L; Jiang L; Li J; Chen X; Chen Z; Chen L; Chen Y
    PLoS One; 2016; 11(9):e0162491. PubMed ID: 27618313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uncovering Molecular Bases Underlying Bone Morphogenetic Protein Receptor Inhibitor Selectivity.
    Alsamarah A; LaCuran AE; Oelschlaeger P; Hao J; Luo Y
    PLoS One; 2015; 10(7):e0132221. PubMed ID: 26133550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 3D-QSAR, docking and molecular dynamics simulations of novel Pyrazolo-pyridazinone derivatives as covalent inhibitors of FGFR1: a scientific approach for possible anticancer agents.
    Hamza S; Abid A; Khanum A; Chohan TA; Saleem H; Maqbool Khan K; Khurshid U; Butt J; Anwar S; Alafnan A; Ansari SA; Qayyum A; Raza A; Chohan TA
    J Biomol Struct Dyn; 2024 Mar; 42(5):2242-2256. PubMed ID: 37211823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects.
    Lu X; Chen H; Patterson AV; Smaill JB; Ding K
    J Med Chem; 2019 Mar; 62(6):2905-2915. PubMed ID: 30403487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2-Oxo-3, 4-dihydropyrimido[4, 5-d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors.
    Li X; Guise CP; Taghipouran R; Yosaatmadja Y; Ashoorzadeh A; Paik WK; Squire CJ; Jiang S; Luo J; Xu Y; Tu ZC; Lu X; Ren X; Patterson AV; Smaill JB; Ding K
    Eur J Med Chem; 2017 Jul; 135():531-543. PubMed ID: 28521156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TAS-120 Cancer Target Binding: Defining Reactivity and Revealing the First Fibroblast Growth Factor Receptor 1 (FGFR1) Irreversible Structure.
    Kalyukina M; Yosaatmadja Y; Middleditch MJ; Patterson AV; Smaill JB; Squire CJ
    ChemMedChem; 2019 Feb; 14(4):494-500. PubMed ID: 30600916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FGFR4 and its novel splice form in myogenic cells: Interplay of glycosylation and tyrosine phosphorylation.
    Kwiatkowski BA; Kirillova I; Richard RE; Israeli D; Yablonka-Reuveni Z
    J Cell Physiol; 2008 Jun; 215(3):803-17. PubMed ID: 18186042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural insights into the interaction of human S100B and basic fibroblast growth factor (FGF2): Effects on FGFR1 receptor signaling.
    Gupta AA; Chou RH; Li H; Yang LW; Yu C
    Biochim Biophys Acta; 2013 Dec; 1834(12):2606-19. PubMed ID: 24063890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular modeling of pyrrolo-pyrimidine based analogs as potential FGFR1 inhibitors: a scientific approach for therapeutic drugs.
    Raza A; Chohan TA; Sarfraz M; Chohan TA; Imran Sajid M; Tiwari RK; Ansari SA; Alkahtani HM; Yasmeen Ansari S; Khurshid U; Saleem H
    J Biomol Struct Dyn; 2023; 41(23):14358-14371. PubMed ID: 36898855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Competition for ligands between FGFR1 and FGFR4 regulates Xenopus neural development.
    Yamagishi M; Okamoto H
    Int J Dev Biol; 2010; 54(1):93-104. PubMed ID: 20013652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and optimization of triazine derivatives as ROCK1 inhibitors: molecular docking, molecular dynamics simulations and free energy calculations.
    Shen M; Zhou S; Li Y; Pan P; Zhang L; Hou T
    Mol Biosyst; 2013 Mar; 9(3):361-74. PubMed ID: 23340525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular mechanisms of the anti-cancer drug, LY2874455, in overcoming the FGFR4 mutation-based resistance.
    Dehghanian F; Alavi S
    Sci Rep; 2021 Aug; 11(1):16593. PubMed ID: 34400727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.